Cholinesterase inhibitors and methyl D-aspartate receptor antagonists delay cognitive decline by approximately six months in dementia patients; however, their safety in end-stage renal disease (ESRD) remains unclear. The gene discussed is BCHE; the disease is chronic kidney disease.